Rochester, New York 14609

  • Corneal Endothelial Cell Changes


The objective of this study is to evaluate the effect on corneal endothelial cell density (cells/mm²) changes at 3 months when mapracorat ophthalmic suspension, 3% is administered QID (four times daily), for 14 days in healthy subjects with a normal ophthalmic history.


Inclusion Criteria: - Must have a Pinhole visual acuity (VA) equal to or better than 20/40 in both eyes. - Must be in good ocular health Exclusion Criteria: - Subjects who have known hypersensitivity or contraindication to the study drug or its components. - Subjects who currently require or are expected to require treatment with any medication listed as a disallowed medication per the Disallowed Therapy section of the protocol. - Any topical ophthalmic medication, including tear substitutes that cannot be discontinued during the study. - Subjects who are monocular (fellow eye is absent or fellow eye's Pinhole VA is worse than 20/200). - Subjects with a history of ocular surgery, or who anticipate ocular surgery in either eye within the study period. - Presence of significant ocular or systemic disease that the Investigator determines could interfere with the study.



Primary Contact:

Study Director
Quintus Ngumah, OD, PhD
Bausch & Lomb Incorporated

Backup Contact:


Location Contact:

Rochester, New York 14609
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source:

Date Processed: June 23, 2021

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on The form below is not enabled.